May 12, 2026 07:30AM
May 12, 2026 07:30AM
Mar 9, 2026 05:16PM
Jan 7, 2026 01:01AM
Aug 8, 2025 08:23AM
Aug 8, 2024 05:51PM
Jun 20, 2024 07:20AM SAB Biotherapeutics (SABS) Rebrands as SAB BIO
Jun 20, 2024 07:20AM
Jun 18, 2024 01:10PM
May 21, 2024 07:15AM
May 21, 2024 07:15AM
Nov 29, 2023 07:30AM
Nov 14, 2023 07:30AM
Oct 19, 2023 07:30AM SAB Biotherapeutics (SABS) Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142
Oct 19, 2023 07:30AM
Apr 26, 2023 08:30AM
Apr 26, 2023 08:30AM
Apr 18, 2023 08:32AM
Apr 18, 2023 08:30AM
Apr 13, 2023 08:31AM
Apr 13, 2023 08:30AM SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
Jan 10, 2023 08:00AM
Jan 10, 2023 08:00AM
Nov 21, 2022 08:15AM
Nov 21, 2022 08:14AM
Nov 21, 2022 08:14AM
Aug 9, 2022 04:30PM
Mar 2, 2022 06:00AM SAB Biotherapeutics (SABS) Announces NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Mar 2, 2022 06:00AM
Mar 2, 2022 06:00AM
Mar 2, 2022 05:53AM
Mar 1, 2022 07:30PM
Jan 24, 2022 06:00AM
Jan 24, 2022 06:00AM
Jan 24, 2022 06:00AM SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Dec 16, 2021 06:01AM
Dec 16, 2021 06:00AM
Dec 16, 2021 06:00AM
Oct 25, 2021 07:39AM
Oct 25, 2021 07:39AM

322,972 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All